American College of Clinical Pharmacy
      Search      Cart
         
  Poster Hall

Sun-24 - Evaluation of major inpatient statin-drug interactions in inpatient older adults prescribed simvastatin compared to all other statins

Scientific Poster Session II - Research & Scholarship Academy Original Research

R&S Academy Orig Research
  Sunday, October 13, 2024
  12:45 PM–02:15 PM

Abstract

Introduction: Statin-drug interaction frequencies occur at rates of 10-25% in outpatients. Simvastatin and lovastatin have the greatest number of listed drug interactions, however, the frequencies that these occur in older adults are rarely reported in the inpatient setting.

Research Question or Hypothesis: There is a higher likelihood of major statin-drug interactions in inpatient older adults prescribed simvastatin compared to other statins.

Study Design: Retrospective cohort study.

Methods: This study was conducted in a rural health system of five inpatient locations. Included patients were aged 65 years and older, and received at least one dose of statin in the inpatient setting from October 1, 2020 to September 30, 2022. The primary outcome was the odds of a major statin-drug interaction between patients prescribed simvastatin compared to all other statins, identified using the Lexicomp® Drug Interactions Module and the drug FDA package inserts. Statistical analyses performed using SPSS were the student’s t-test or Mann-Whitney U test, and Chi-square or Fisher’s exact test, as appropriate.

Results: Of 1375 patients evaluated for study inclusion, 1291 patients were included in the final analysis. In total, 1072 (83.0%) patients were prescribed atorvastatin, 202 (15.6%) prescribed simvastatin, 12 (0.9%) prescribed rosuvastatin, and 5 (0.4%) pravastatin. Major statin-drug interactions, occurred in 11 patients (5.4%) in the simvastatin group and 5 (0.5%) in the other statin group (OR, 12.49; 95% CI, 4.291, 36.34; p-Value <0.001).

Conclusion: Among patients aged 65 years and older receiving an inpatient statin, those who received simvastatin had a 12 times higher odds of a major statin-drug interaction compared to other statins. The results suggest that replacement of simvastatin with an alternative inpatient formulary statin could reduce the likelihood of prescribing major statin-drug interactions.

Presenting Author

Rachel Klosko PharmD

Authors

Gordon Huang PharmD
Binghamton University School of Pharmacy and Pharmaceutical Sciences

Brett Krummenacker PharmD
Binghamton University School of Pharmacy and Pharmaceutical Sciences

Jordan Major PharmD
Binghamton University School of Pharmacy and Pharmaceutical Sciences

Michael Reiver PharmD
Binghamton University School of Pharmacy and Pharmaceutical Sciences

Rachel Saroka PharmD
Guthrie Robert Packer Hospital

Saurabh Sharma MD
Guthrie Robert Packer Hospital

Keira Strong PharmD
Binghamton University School of Pharmacy and Pharmaceutical Sciences

Lucas Whittacker PharmD
Guthrie Robert Packer Hospital

Cookies

This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.